Prostate Specific Membrane Antigen Targeted Positron Emission Tomography of Primary Prostate Cancer: Assessing Accuracy with Whole Mount Pathology

被引:15
|
作者
Bahler, Clinton D. [1 ]
Green, Mark [2 ]
Hutchins, Gary D. [2 ]
Cheng, Liang [3 ]
Magers, Martin J. [3 ]
Fletcher, James [2 ]
Koch, Michael O. [1 ]
机构
[1] Indiana Univ, Dept Urol, Indianapolis, IN 46204 USA
[2] Indiana Univ, Dept Radiol, Indianapolis, IN 46204 USA
[3] Indiana Univ, Dept Pathol, Indianapolis, IN 46204 USA
基金
美国国家卫生研究院;
关键词
prostatic neoplasms; positron-emission tomography; pathology; surgical; risk; early detection of cancer; RADICAL PROSTATECTOMY; GLEASON PATTERN-4; TUMOR VOLUME; MEN; PROGRESSION; BIOPSY; PERCENTAGE; PREDICTOR; PET/CT;
D O I
10.1097/JU.0000000000000501
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated which lesions are detected and missed on [Ga-68]Ga-PSMA (prostate specific membrane antigen)-11 positron emission tomography in patients with primary prostate cancer. Materials and Methods: Patients undergoing radical prostatectomy were enrolled in this prospective observational study. Patients underwent [Ga-68] Ga-PSMA-11 positron emission tomography/computerized tomography or positron emission tomography/magnetic resonance imaging prior to surgery and received a dose of [Ga-68] Ga-PSMA-11 intraoperatively for positron emission tomography of extirpated specimens. Whole mount pathology was performed with lesion and intralesion based analysis to determine the characteristics of lesions detected or not detected by PSMA positron emission tomography. Lesion volume was determined by planimetry and clinically significant lesion volume was calculated as lesion volume x fraction pattern 4/5. Results: On whole mount analysis 30 cancerous lesions were found in a total of 15 patients, including 4, 15, 4, 1 and 6 which were Grade Group 1, 2, 3, 4 and 5, respectively. PSMA-positron emission tomography detected 100% of primary/index lesions and 8 of 11 (82%) secondary lesions. All Grade Group 3-5 lesions were detected vs 12 of 15 Grade Group 2 lesions. When comparing Grade Group 2 vs 3-5, lesion size was similar (p = 0.48) but the standardized uptake value was lower for Grade Group 2 vs 3-5 (5.3 vs 7.9, p = 0.03). The 3 missed lesions showed 10% or less of pattern 4 and a Gleason pattern 4/5 volume of less than 0.1 cm(3). Conclusions: PSMA positron emission tomography detected 100% of primary/index lesions in this study. The 3 missed secondary lesions were small and had a low percent of pattern 4. This argues for further study to better understand what defines clinically significant prostate cancer, which would assist in determining whether small lesions that become challenging to detect by [Ga-68]Ga-PSMA-11 positron emission tomography confer a risk to the patient.
引用
收藏
页码:92 / 99
页数:8
相关论文
共 50 条
  • [1] Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer
    Rhee, H.
    Thomas, P.
    Shepherd, B.
    Gustafson, S.
    Vela, I.
    Russell, P. J.
    Nelson, C.
    Chung, E.
    Wood, G.
    Malone, G.
    Wood, S.
    Heathcote, P.
    JOURNAL OF UROLOGY, 2016, 196 (04) : 1261 - 1266
  • [2] Microcosting Study of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Prostate Cancer
    Parkinson, Bonny
    Sharma, Rajan
    Jeet, Varinder
    Song, Rachel
    Hoyle, Martin
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 17 - 22
  • [3] Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot
    Jiao, Jianhua
    Zhang, Jingliang
    Li, Zeyu
    Wen, Weihong
    Cui, Chaochao
    Zhang, Qiang
    Wang, Jing
    Qin, Weijun
    CANCER LETTERS, 2022, 548
  • [4] Making the case for prostate-specific membrane antigen-targeted positron emission tomography/computed tomography in suspected prostate cancer
    Singh, Harmandeep
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2020, 35 (04): : 281 - 282
  • [5] Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer
    Afaq, Asim
    Bomanji, Jamshed
    BRITISH MEDICAL BULLETIN, 2018, 128 (01) : 37 - 48
  • [6] Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine
    Bouchelouche, Kirsten
    Choyke, Peter L.
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (03) : 216 - 221
  • [7] The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature
    Manfredi, Celeste
    Fernandez-Pascual, Esau
    Arcaniolo, Davide
    Emberton, Mark
    Sanchez-Salas, Rafael
    Guix, Carlos Artigas
    Bianco, Fernando
    Cathcart, Paul
    Murphy, Declan G.
    Counago, Felipe
    Martinez-Ballesteros, Claudio
    Verze, Paolo
    Ignacio Martinez-Salamanca, Juan
    EUROPEAN UROLOGY FOCUS, 2022, 8 (04): : 942 - 957
  • [8] The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer
    Meijer, Dennie
    de Barros, Hilda A.
    van Leeuwen, Pim J.
    Bodar, Yves J. L.
    van der Poel, Henk G.
    Donswijk, Maarten L.
    Hendrikse, N. Harry
    van Moorselaar, R. Jeroen A.
    Nieuwenhuijzen, Jakko A.
    Oprea-Lager, Daniela E.
    Vis, Andre N.
    JOURNAL OF UROLOGY, 2021, 205 (06) : 1655 - 1661
  • [9] New frontiers in focal therapy for prostate cancer: Prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging
    Manfredi, Celeste
    Fernandez-Pascual, Esau
    Linares-Espinos, Estefania
    Counago, Felipe
    Martinez-Salamanca, Juan Ignacio
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (02): : 61 - 68
  • [10] Research progress on prostate-specific membrane antigen ligand positron emission tomography imaging of prostate cancer
    Li Y.
    Liu B.
    Yuan Y.
    Qin W.
    Shengwu Yixue Gongchengxue Zazhi/Journal of Biomedical Engineering, 2022, 39 (06): : 1263 - 1268